Imuracetam
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Our verdict SKIP-PERMANENT HIGH
Imuracetam (developmental code UCB-G218) is a UCB Pharma 1970s-era racetam candidate that was never marketed and has no published human clinical trials, no commercial form, no available reference standard for research-chem synthesis, and no community sourcing pathway. PubMed returns zero direct results (only auto-correction to the unrelated compound dimiracetam). It is effectively vaporware in the user/biohacker sense — there is no actionable compound to source, dose, or stack. The user should consult the documented, available racetams instead (piracetam, aniracetam, oxiracetam, phenylpiracetam, etc.).
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
For all archetypes | NOT-AVAILABLE | Imuracetam cannot be obtained. Decision-matrix entries become moot. If a reader wants the racetam class for any of the standard archetype use cases, the table above directs them to the actually-available members of the family. |
- For all archetypesNOT-AVAILABLE
Imuracetam cannot be obtained. Decision-matrix entries become moot. If a reader wants the racetam class for any of the standard archetype use cases, the table above directs them to the actually-available members of the family.
▸ Verdict change log
- 2026-05-06 — Initial verdict: SKIP-PERMANENT / HIGH confidence. Vaporware. Zero PubMed results, no commercial source, no community use base. Documented for completeness only — anyone who comes across the name elsewhere can verify here that it's not actionable.
▸ Open questions / gaps Open
None actionable. The compound has no commercial future as of 2026 — UCB has not revived the program in 50 years and there is no orphan-drug or repurposing pathway active. If a third party were to synthesize it for research, fresh PK / pharmacology characterization would be needed before any human use; that work is not happening as of the last literature search.
▸ Cross-references
If the user came here looking for a racetam recommendation, the wiki has thorough files on the actually-available members of the family. Recommendations by use case for Dylan-archetype:
| Compound | Wiki file | Use case | Sourcing | Verdict for Dylan |
|---|---|---|---|---|
| Piracetam | piracetam.md |
Parent racetam; mild general cognitive support; vegetarian / methylation-modulator angle; very well-tolerated | Research-chem (US); Rx in EU for cognitive disorders | OPTIONAL-ADD if cholinergic stack tested |
| Aniracetam | aniracetam.md |
Anxiolytic-leaning racetam; AMPA modulation; fat-soluble (take with food) | Research-chem; widely available | OPTIONAL-ADD for anxiety-prone cognitive days |
| Oxiracetam | oxiracetam.md |
Mildly stimulating racetam; logical/analytical work | Research-chem | OPTIONAL-ADD for analytical workloads |
| Pramiracetam | pramiracetam.md |
Higher-potency racetam; cholinergic-dependent; needs choline source | Research-chem | OPTIONAL-ADD with citicoline base (Dylan has) |
| Phenylpiracetam | phenylpiracetam.md |
Stimulating racetam (phenotropil); WADA-banned in competition; tolerance fast | Russian gray-market / research-chem | PRN-only (cycling required) — see file |
| Coluracetam | coluracetam.md |
High-affinity choline uptake enhancer; mood/visual effects | Research-chem | WATCH-LIST |
| Nefiracetam | nefiracetam.md |
Cholinergic + GABAergic; possible anti-apathy effect | Research-chem (limited) | WATCH-LIST |
| Fasoracetam | fasoracetam.md |
mGluR upregulation; anxiolysis | Research-chem | WATCH-LIST |
| Noopept | noopept.md |
Not strictly a racetam but adjacent (Russian peptide); BDNF/NGF upregulation | Research-chem; Russian | OPTIONAL-ADD |
| Levetiracetam (Keppra) | levetiracetam.md |
SV2A binder; FDA-approved anticonvulsant; not a nootropic | US Rx | NOT-RELEVANT for cognition |
| Brivaracetam (Briviact) | brivaracetam.md |
Newer SV2A binder; anticonvulsant | US Rx | NOT-RELEVANT for cognition |
For Dylan's V5 trajectory specifically, the racetam slot is best filled by phenylpiracetam PRN for cognitive-demand days (with strict cycling per file) or aniracetam for anxiety-leaning sessions. Piracetam is the gentlest entry point if running a chronic racetam baseline. None of the racetam options change Dylan's V5 core stack (modafinil + bromantane + Adamax + Semax + apigenin + ALCAR + Cerebrolysin cycles) — racetams are a family worth knowing exists but rarely the highest-leverage move in this archetype.
▸ Sources (full, with our context)
- Wikipedia — Imuracetam — confirms UCB-G218 developmental code, 1970s development, never marketed; stub-class article reflecting absence of literature
- PubMed search for "imuracetam" — returns zero direct results; auto-redirects to dimiracetam (unrelated compound)
- Medsafe NZ — Classification status of racetams — regulatory survey listing imuracetam alongside other racetams for completeness; no clinical data
- See
piracetam.md,aniracetam.md,phenylpiracetam.mdfor the actually-available racetam options Dylan should consider instead